5 results on '"Dagan, Noa"'
Search Results
2. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting.
- Author
-
Mittelman M, Magen O, Barda N, Dagan N, Oster HS, Leader A, and Balicer R
- Subjects
- Aged, Female, Humans, Male, Middle Aged, BNT162 Vaccine administration & dosage, BNT162 Vaccine immunology, COVID-19 immunology, COVID-19 mortality, COVID-19 prevention & control, Hematologic Neoplasms immunology, Hematologic Neoplasms mortality, SARS-CoV-2 immunology
- Abstract
Evidence regarding the effectiveness of COVID-19 vaccine in patients with impaired immunity is limited. Initial observations suggest a lower humoral response in these patients. We evaluated the relative effectiveness of the mRNA BNT162b2 vaccine in patients with hematological neoplasms compared with matched controls. Data on patients with hematological neoplasms after 2 vaccine doses were extracted and matched 1:1 with vaccinated controls. Subpopulation analyses focused on patients receiving therapy for hematological neoplasm, patients without treatment who were only followed, and recipients of specific treatments. The analysis focused on COVID-19 outcomes from days 7 through 43 after the second vaccine dose in these areas: documented COVID-19 infection by polymerase chain reaction; symptomatic infection; hospitalizations; severe COVID-19 disease; and COVID-19-related death. In a population of 4.7 million insured people, 32 516 patients with hematological neoplasms were identified, of whom 5017 were receiving therapy for an active disease. Vaccinated patients with hematological neoplasms, compared with vaccinated matched controls, had an increased risk of documented infections (relative risk [RR] 1.60, 95% CI 1.12-2.37); symptomatic COVID-19 (RR 1.72, 95% CI 1.05-2.85); COVID-19-related hospitalizations (RR 3.13, 95% CI 1.68-7.08); severe COVID-19 (RR 2.27, 95% CI 1.18-5.19); and COVID-19-related death (RR 1.66, 95% CI 0.72-4.47). Limiting the analysis to patients on hematological treatments showed a higher increased risk. This analysis shows that vaccinated patients with hematological neoplasms, in particular patients receiving treatment, suffer from COVID-19 outcomes more than vaccinated individuals with intact immune system. Ways to enhance COVID-19 immunity in this patient population, such as additional doses, should be explored., (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
3. Previously undiagnosed cancer in patients with arterial thrombotic events - A population-based cohort study.
- Author
-
Leader A, Dagan N, Barda N, Goldberg I, Raanani P, Spectre G, Balicer R, and Gafter-Gvili A
- Subjects
- Cohort Studies, Humans, Incidence, Middle Aged, Risk Factors, Neoplasms diagnosis, Neoplasms epidemiology, Stroke diagnosis, Stroke epidemiology, Thromboembolism diagnosis, Thromboembolism epidemiology, Thrombosis diagnosis, Thrombosis epidemiology
- Abstract
Background: Emerging data suggest increased arterial thrombosis risk in the months preceding a cancer diagnosis., Objectives: To assess whether patients without documented vascular risk factors or pre-existing cardiovascular disease have a higher relative risk of cancer 12 months after arterial thrombotic events (ATE), compared to unselected patients., Patients/methods: A population-based cohort study of Clalit Health Services (CHS) database included CHS members ≥25 years without prior cancer or ATE (n = 2 804 584). An iterative matching process selected 10 potential controls chronologically for each consecutive exposed, age- and sex-matched (actual controls drawn 1:1 from a lot). Study exposure, ATE, was defined as ischemic stroke, transient ischemic attack, myocardial infarction or systemic arterial thromboembolism during hospitalization. The outcome was newly-diagnosed cancer within 12 months, based on Israeli national cancer registry. Cox proportional hazards multivariate regression calculated hazard ratio (HR) for outcomes, adjusted for cancer risk factors. Analysis also performed for three subgroups: age ≤50 years; no cardiovascular risk factors; no prior cardiovascular disease., Results: The full ATE and matched control cohorts included 43 108 patients. The 12-month cumulative incidence of cancer (95% confidence interval) was 0.020 (0.019-0.022) in the ATE cohort and 0.012 (0.011-0.013) in controls, corresponding to an adjusted HR of 1.665 (1.489-1.862). The relative risk of cancer was high in all subgroups up to a HR of 3.754 (1.912-7.372) in patients without cardiovascular risk factors., Conclusion: There is an increased risk of previously undiagnosed cancer at 12 months after ATE, especially in patients without documented vascular risk factors or pre-existent cardiovascular disease., (© 2021 International Society on Thrombosis and Haemostasis.)
- Published
- 2022
- Full Text
- View/download PDF
4. The role of observational studies based on secondary data in studying SARS-CoV-2 vaccines.
- Author
-
Barda N and Dagan N
- Subjects
- Antibodies, Neutralizing immunology, Humans, SARS-CoV-2, COVID-19 prevention & control, COVID-19 Vaccines
- Published
- 2022
- Full Text
- View/download PDF
5. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
- Author
-
Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, Reis BY, and Balicer RD
- Subjects
- Adult, Aged, COVID-19 epidemiology, COVID-19 virology, Female, Humans, Israel epidemiology, Male, Mass Vaccination, Middle Aged, Pandemics prevention & control, Prognosis, SARS-CoV-2, BNT162 Vaccine, COVID-19 prevention & control, Immunization, Secondary, Vaccine Efficacy
- Abstract
Background: Many countries are experiencing a resurgence of COVID-19, driven predominantly by the delta (B.1.617.2) variant of SARS-CoV-2. In response, these countries are considering the administration of a third dose of mRNA COVID-19 vaccine as a booster dose to address potential waning immunity over time and reduced effectiveness against the delta variant. We aimed to use the data repositories of Israel's largest health-care organisation to evaluate the effectiveness of a third dose of the BNT162b2 mRNA vaccine for preventing severe COVID-19 outcomes., Methods: Using data from Clalit Health Services, which provides mandatory health-care coverage for over half of the Israeli population, individuals receiving a third vaccine dose between July 30, 2020, and Sept 23, 2021, were matched (1:1) to demographically and clinically similar controls who did not receive a third dose. Eligible participants had received the second vaccine dose at least 5 months before the recruitment date, had no previous documented SARS-CoV-2 infection, and had no contact with the health-care system in the 3 days before recruitment. Individuals who are health-care workers, live in long-term care facilities, or are medically confined to their homes were excluded. Primary outcomes were COVID-19-related admission to hospital, severe disease, and COVID-19-related death. The third dose effectiveness for each outcome was estimated as 1 - risk ratio using the Kaplan-Meier estimator., Findings: 1 158 269 individuals were eligible to be included in the third dose group. Following matching, the third dose and control groups each included 728 321 individuals. Participants had a median age of 52 years (IQR 37-68) and 51% were female. The median follow-up time was 13 days (IQR 6-21) in both groups. Vaccine effectiveness evaluated at least 7 days after receipt of the third dose, compared with receiving only two doses at least 5 months ago, was estimated to be 93% (231 events for two doses vs 29 events for three doses; 95% CI 88-97) for admission to hospital, 92% (157 vs 17 events; 82-97) for severe disease, and 81% (44 vs seven events; 59-97) for COVID-19-related death., Interpretation: Our findings suggest that a third dose of the BNT162b2 mRNA vaccine is effective in protecting individuals against severe COVID-19-related outcomes, compared with receiving only two doses at least 5 months ago., Funding: The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute., Competing Interests: Declaration of interests NB, ND, and RDB report institutional grants to Clalit Research Institute from Pfizer outside the submitted work and unrelated to COVID-19, with no direct or indirect personal benefits. MAH reports grants from the US National Institutes of Health (NIH) and US Department of Veterans Affairs, and personal fees from Cytel and ProPublica. ML reports grants from Pfizer, NIH, the UK National Institute for Health Research, the US Centers for Disease Control and Prevention, Open Philanthropy Project, the Wellcome Trust, and Pfizer; personal fees from Merck, Bristol Meyers Squibb, Sanofi Pasteur, and Janssen; and unpaid advice given on Covid vaccines or vaccine studies to One Day Sooner, Pfizer, AstraZeneca, Janssen, and COVAXX (United Biosciences), outside the submitted work. BYR reports grants from NIH outside the submitted work. All other authors declare no competing interests., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.